GLP-1 & Obesity
The profitable obesity-drug duopoly + the oral challenger
The obesity / GLP-1 drug wave — the most fundamentally-grounded 10x theme, anchored by two profitable mega-cap leaders with real, large revenue today, plus a high-risk clinical-stage challenger. Curated structure; live delayed prices. Not investment advice.
1
The Duopoly Leaders
Two profitable mega-caps that own today's GLP-1 market and are racing on next-gen oral formulations.
2
The Clinical-Stage Challenger
The high-risk, high-reward third entrant — binary on Phase III trial readouts.
Curated structure · live delayed prices from public data · for reference only · not investment advice